Attached files
| file | filename |
|---|---|
| EX-99.B - EXHIBIT 99B - MERA PHARMACEUTICALS INC | e3086_ex99b.htm |
| EX-99.A - EXHIBIT 99A - MERA PHARMACEUTICALS INC | e3086_ex99a.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) : September 10, 2021
MERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 333-23460 | 04-3683628 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
8275 S. Eastern Ave. Suite 200, Las Vegas, NV 89123
(Address of principal executive offices) (Zip Code)
604-500-4157
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Items |
Mera Pharmaceuticals, Inc. financials attached.
Exhibits
| 99a | Balance Sheet | |
| 99b | Profit and Loss |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Mera Pharmaceuticals, Inc. | ||
| Dated: September 10, 2021 | By: | |
| Name: | Benny Doro | |
| Title: | Chief Executive Officer and President | |